ES3053505T3 - Tri-substituted imidazoles for the inhibition of tgf beta and methods of treatment - Google Patents

Tri-substituted imidazoles for the inhibition of tgf beta and methods of treatment

Info

Publication number
ES3053505T3
ES3053505T3 ES18823320T ES18823320T ES3053505T3 ES 3053505 T3 ES3053505 T3 ES 3053505T3 ES 18823320 T ES18823320 T ES 18823320T ES 18823320 T ES18823320 T ES 18823320T ES 3053505 T3 ES3053505 T3 ES 3053505T3
Authority
ES
Spain
Prior art keywords
group
compound
carbon atoms
cancer
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18823320T
Other languages
English (en)
Spanish (es)
Inventor
J Scott Sawyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clavius Pharmaceuticals LLC
Original Assignee
Clavius Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clavius Pharmaceuticals LLC filed Critical Clavius Pharmaceuticals LLC
Application granted granted Critical
Publication of ES3053505T3 publication Critical patent/ES3053505T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES18823320T 2017-03-23 2018-03-23 Tri-substituted imidazoles for the inhibition of tgf beta and methods of treatment Active ES3053505T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762475451P 2017-03-23 2017-03-23
PCT/US2018/024133 WO2019005241A1 (en) 2017-03-23 2018-03-23 TRI-SUBSTITUTED IMIDAZOLES FOR INHIBITION OF TGF-BETA AND METHODS OF TREATMENT

Publications (1)

Publication Number Publication Date
ES3053505T3 true ES3053505T3 (en) 2026-01-22

Family

ID=64741862

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18823320T Active ES3053505T3 (en) 2017-03-23 2018-03-23 Tri-substituted imidazoles for the inhibition of tgf beta and methods of treatment

Country Status (5)

Country Link
US (2) US11124509B2 (cg-RX-API-DMAC10.html)
EP (1) EP3600294B1 (cg-RX-API-DMAC10.html)
JP (2) JP2020512400A (cg-RX-API-DMAC10.html)
ES (1) ES3053505T3 (cg-RX-API-DMAC10.html)
WO (1) WO2019005241A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3053505T3 (en) * 2017-03-23 2026-01-22 Clavius Pharmaceuticals Llc Tri-substituted imidazoles for the inhibition of tgf beta and methods of treatment
WO2020041562A1 (en) 2018-08-22 2020-02-27 Clavius Pharmaceuticals, Llc Substituted imidazoles for the inhibition of tgf-beta and methods of treatment
CA3117710A1 (en) 2018-12-11 2020-06-18 Theravance Biopharma R&D Ip, Llc Alk5 inhibitors
KR20220104208A (ko) 2019-11-22 2022-07-26 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Alk5 억제제로서 치환된 1,5-나프티리딘 또는 퀴놀린
KR102509625B1 (ko) * 2022-03-25 2023-03-14 주식회사 메드팩토 TGF-β 저해제의 합성에 유용한 중간체 및 이를 이용한 TGF-β 저해제 제조방법
AU2023449764A1 (en) * 2023-05-22 2025-12-11 Iregene Therapeutics Co., Ltd. Pyrazolecarbonyl piperazinone compound, pharmaceutical composition and use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001163861A (ja) * 1999-12-07 2001-06-19 Nippon Soda Co Ltd ジフェニルイミダゾール化合物および農園芸用殺菌剤
NZ549003A (en) * 2004-03-05 2009-07-31 Taisho Pharmaceutical Co Ltd Thiazole derivative as an ALK5 inhibitor
US8188113B2 (en) * 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
WO2008094556A2 (en) * 2007-01-30 2008-08-07 Biogen Idec Ma Inc. Imidazolone compounds as tgf-beta family type i receptors, alk5 and/or alk4 antagonists
AU2009226136B2 (en) * 2008-03-17 2013-08-15 Ambit Biosciences Corporation Quinazoline derivatives as RAF kinase modulators and methods of use thereof
WO2009115572A2 (en) 2008-03-21 2009-09-24 Novartis Ag Novel heterocyclic compounds and uses therof
CN102131801B (zh) * 2008-06-25 2015-04-08 福拉姆医药股份有限公司 1,2-二取代的杂环化合物
JP2012514044A (ja) * 2008-12-30 2012-06-21 ミレニアム ファーマシューティカルズ, インコーポレイテッド Rafキナーゼ阻害剤として有用なヘテロアリール化合物
US8080568B1 (en) 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
RU2612958C2 (ru) 2011-07-13 2017-03-14 Ск Кемикалз Ко., Лтд. 2-пиридилзамещенные имидазолы в качестве ингибиторов alk5 и/или alk4
JO3336B1 (ar) * 2014-10-07 2019-03-13 Lilly Co Eli مركبات أمينو بيريديلوكسي بيرازول
EP3221318B1 (en) 2014-11-21 2021-08-25 Rigel Pharmaceuticals, Inc. Fused imidazole derivatives as tgf-beta inhibitors
JP6836998B2 (ja) * 2015-03-02 2021-03-03 ライジェル ファーマシューティカルズ, インコーポレイテッド TGF−β阻害剤
WO2018068759A1 (zh) 2016-10-14 2018-04-19 江苏恒瑞医药股份有限公司 五元杂芳环并桥环类衍生物、其制备方法及其在医药上的应用
ES3053505T3 (en) 2017-03-23 2026-01-22 Clavius Pharmaceuticals Llc Tri-substituted imidazoles for the inhibition of tgf beta and methods of treatment

Also Published As

Publication number Publication date
WO2019005241A1 (en) 2019-01-03
US20220073514A1 (en) 2022-03-10
US20200239462A1 (en) 2020-07-30
JP2020512400A (ja) 2020-04-23
EP3600294A1 (en) 2020-02-05
EP3600294B1 (en) 2025-09-03
US11845745B2 (en) 2023-12-19
EP3600294A4 (en) 2020-08-26
JP2023052027A (ja) 2023-04-11
US11124509B2 (en) 2021-09-21

Similar Documents

Publication Publication Date Title
US11845745B2 (en) Tri-substituted imidazoles for the inhibition of TGF beta and methods of treatment
Boltjes et al. The groebke‐blackburn‐bienaymé reaction
EP3902803B1 (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
BR112021012599A2 (pt) Inibidores aza-heterobicíclicos de mat2a e métodos de uso para tratamento de câncer
DK2137162T3 (en) Organic compounds and their applications
JP5992054B2 (ja) ピラゾロピロリジン化合物
AU2009272719B2 (en) Pyridazine derivatives as Smo inhibitors
TW201833102A (zh) 作為ehmt2抑制劑之胺取代的雜環化合物及其使用方法
ES2687475T3 (es) Nuevos derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
BRPI0709082A2 (pt) derivados de indazol substituìdos, sua fabricação e uso como agentes farmacêuticos
EP1957078A2 (en) Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
ES2732437T3 (es) Moduladores del receptor de CXCR7
JP7147048B2 (ja) Tgf-ベータを阻害するための置換イミダゾールおよび処置方法
BR112013029935B1 (pt) Compostos inibidores de diacilglicerol aciltransferase e composição farmacêutica compreende-os
AU2016368257C1 (en) Five-membered heterocyclic amides wnt pathway inhibitor
JP2019533650A (ja) Ehmt2阻害剤としての置換された融合二環式または三環式複素環化合物
WO2023150681A1 (en) Inhibitors of raf kinases
EP3209665A1 (en) Heteroaryl substituted pyrrolotriazine amine compounds as pi3k inhibitors
WO2023078319A1 (zh) 一种可抑制il-17a的杂环化合物及其用途
JP2023520595A (ja) ピラゾロピリダジノン化合物、その医薬組成物及びその用途
JP2025504495A (ja) Rasシグナル伝達の調節因子としての縮合複素環式化合物
Abu-Hashem et al. Recent advances in the chemistry of oxadiazepine derivatives: A significant leap in synthetic heterocycles and biological activity
RU2804709C9 (ru) Соединения для лечения некоторых лейкозов
CN119019402A (zh) 作为lrrk2激酶抑制剂的多环化合物及其制备方法和用途
OA20638A (en) Aza-heterobicyclic inhibitors Of MAT2A and methods of use for treating cancer.